Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis

The clinical data on the biologic disease-modifying antirheumatic drug (bDMARD) use in late-onset ankylosing spondylitis (LOAS) is limited. Thus, this study aimed to evaluate the drug efficacy and retention rate of bDMARDs in LOAS and compare it to young-onset ankylosing spondylitis (YOAS). Data of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Se Hee, Kim, Hae-Rim, Lee, Sang-Heon, Shin, Kichul, Kim, Hyoun-Ah, Min, Hong Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566570/
https://www.ncbi.nlm.nih.gov/pubmed/34732807
http://dx.doi.org/10.1038/s41598-021-01132-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566570/
https://www.ncbi.nlm.nih.gov/pubmed/34732807
http://dx.doi.org/10.1038/s41598-021-01132-6

Ejemplares similares